UNSPSC 41141916: Amylase test system

In this classification, Amylase test system connotes a device used to measure Amylase levels. US FDA regulates Amylase test system under 21 CFR 862.1070 and under FDA product code JFJ.

UNSPSC 41141916 Amylase test system (Commodity) covers forensic and clinical laboratory testing kits and reagents that state and local governments procure for substance analysis, toxicology screening, and disease surveillance. Recent solicitations show state and local agencies buying Direct ELISA testing kits for drug screening (cannabinoids, opiates, benzodiazepines, and other controlled substances), certified reference drug standards for method validation and evidentiary sample analysis, and virus detection test kits (West Nile Virus and Dengue) for mosquito surveillance programs. The issuing-body mix includes state departments of public safety, health services, law enforcement, and financial regulation, county forensic laboratories, and county health departments operating forensic or public-health labs. Texas appears as a repeat buyer, with recent solicitations from the Texas Department of Public Safety and the Texas Health and Human Services Commission.

Geographic activity concentrates in Texas and Florida. Representative recent opportunities include the Texas Department of Public Safety IFB 405-26R0008445A (posted July 9, 2026, due July 23, 2026) for Direct ELISA testing kits across 12 drug-category line items with estimated unit quantities from 3 to 30 per item; Pinellas County, Florida ITQ 26-0305-ITQ (posted and due April 23, 2026) for 131 line items of certified reference drug standards under the Paul Coverdell Forensic Sciences Improvement Act Program with $49,034.00 designated for equipment and supplies, preferencing Pinellas County Small Business Enterprises; the Illinois Department of Financial and Professional Regulation's sole-source joint purchase agreement (posted May 4, 2026, due May 20, 2026) for the RAMP mosquito testing system including West Nile Virus and Dengue test kits distributed nationwide; and the Texas Health and Human Services Commission IFB HHS0016902v2 (due January 29, 2026) for QIAxcel and QIAamp DNA screening kits with historical spend of $25,050.00 to $30,000.00 in Fiscal Year 2025.